Electromed (ELMD) Stock Price, News & Analysis

Company Overview

Electromed Inc. (NYSE: ELMD) develops and manufactures sleep therapy products designed to support individuals with breathing disorders such as obstructive sleep apnea. The company’s core business activities include the design, production and distribution of continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) accessories. Electromed’s focus on supplying both disposable and reusable components allows durable medical equipment providers to offer comprehensive therapy solutions to patients.

The company’s product portfolio encompasses masks, mask cushions, headgear, tubing, filters and humidification components. Electromed produces private-label and branded items that meet or exceed industry quality standards, supplying home healthcare providers, sleep clinics and respiratory therapists. Its integrated manufacturing processes—from material sourcing to final assembly—aim to ensure product consistency, quick turnaround times and cost efficiencies for its customers.

Founded in 2003 and headquartered in Jacksonville, Florida, Electromed operates manufacturing and distribution facilities within the United States and maintains a growing international customer base. The company’s vertically integrated operations and emphasis on research and development support ongoing product innovation and regulatory compliance. Electromed’s management team draws on decades of experience in the medical device sector to guide strategic growth and expand market reach.

Key Stats

• Today's Range: $23.75 to $25.00
• 50-Day Range: $18.13 to $26.61
• 52-Week Range: $17.73 to $35.56
• Volume: 54,060 shs
• Average Volume: 85,295 shs
• Market Capitalization: $199.37 million
• P/E Ratio: 31.84
• Dividend Yield: N/A
• Price Target: $36.25
• Consensus Rating: Buy

Electromed Stock Analysis - MarketRank™

Electromed scored higher than 77% of companies evaluated by MarketBeat, and ranked 281st out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Electromed has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Electromed has a consensus price target of $36.25, representing about 51.8% upside from its current price of $23.88.

Amount of Analyst Coverage

Electromed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Electromed is 31.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of Electromed is 31.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.06.

Price to Book Value per Share Ratio

Electromed has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.28% of the float of Electromed has been sold short.

Short Interest Ratio / Days to Cover

Electromed has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Electromed has recently decreased by 6.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Electromed does not currently pay a dividend.

Dividend Growth

Electromed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.28% of the float of Electromed has been sold short.

Short Interest Ratio / Days to Cover

Electromed has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Electromed has recently decreased by 6.35%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.38

News Sentiment

Electromed has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Electromed this week, compared to 2 articles on an average week.

Search Interest

12 people have searched for ELMD on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Electromed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Electromed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,598,480.00 in company stock.

Percentage Held by Insiders

14.00% of the stock of Electromed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.82% of the stock of Electromed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELMD Stock Analysis - Frequently Asked Questions

How have ELMD shares performed this year?

Electromed's stock was trading at $29.55 at the start of the year. Since then, ELMD stock has decreased by 19.2% and is now trading at $23.88.

How were Electromed's earnings last quarter?

Electromed, Inc. (NYSE:ELMD) released its quarterly earnings results on Tuesday, November, 12th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.13. The business earned $14.67 million during the quarter. Electromed had a trailing twelve-month return on equity of 15.71% and a net margin of 11.34%.

How will Electromed's stock buyback program work?

Electromed's board authorized a stock buyback program on Monday, March 10th 2025, which permits the company to buy back $5,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 2.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

Who are Electromed's major shareholders?

Top institutional investors of Electromed include Acadian Asset Management LLC (2.84%), Geode Capital Management LLC (1.85%), Gamco Investors INC. ET AL (1.69%) and Hunter Associates Investment Management LLC (1.28%). Insiders that own company stock include Kathleen Skarvan and Andrew Summers.
View institutional ownership trends.

How do I buy shares of Electromed?

Shares of ELMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Electromed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Electromed investors own include NVIDIA (NVDA), Enterprise Products Partners (EPD), Energy Transfer (ET), Meta Platforms (META), Pfizer (PFE), TransEnterix (TRXDW) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 9/13/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ELMD
• CIK: 1488917
• Web: smartvest.com
• Phone: (952) 758-9299
• Fax: 866-758-5077
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Electromed: $36.25
• High Price Target: $38.00
• Low Price Target: $35.00
• Potential Upside/Downside: +51.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.84
• Trailing P/E Ratio: 31.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $5.15 million
• Net Margins: 11.34%
• Pretax Margin: 15.57%
• Return on Equity: 15.71%
• Return on Assets: 13.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.10
• Quick Ratio: 4.74

Sales & Book Value

• Annual Sales: $64 million
• Price / Sales: 3.12
• Cash Flow: $0.58 per share
• Price / Cash Flow: 41.36
• Book Value: $5.10 per share
• Price / Book: 4.68

Miscellaneous

• Outstanding Shares: 8,349,000
• Free Float: 7,359,000
• Market Cap: $199.37 million
• Optionable: Optionable
• Beta: 0.54